Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster

Local and Regional Anesthesia

Volumn 3, Issue 1, 2010, Pages 77-83

  Correa Illanes, Gerardo ^a   Calderón, Wilfredo ^b   Roa, Ricardo ^b   Piñeros, José Luis ^b   Dote, Jacqueline ^b   Medina, David ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL DEL TRABAJADOR   (Chile)

Author keywords

Chronic post traumatic pain; Chronic postsurgical pain; Lidocaine medicated plaster; Neuropathic pain

Indexed keywords

LIDOCAINE; PARACETAMOL; TRAMADOL; UNCLASSIFIED DRUG; VERSATIS;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BURN SCAR; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PATIENT COMPLIANCE; POSTTRAUMATIC PAIN; PROSPECTIVE STUDY; SCAR FORMATION; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE;

EID: 77957320756     PISSN: None     EISSN: 11787112     Source Type: Book Series    
DOI: 10.2147/LRA.S13082     Document Type: Article

References (30)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-1635.
2. Hernández JN, Hernández J, Moreno C. Use of lidocaine patches in the relief of localised neuropathic pain. Rev Iberoamericana del Dolor. 2009;1(4):13-28.
3. de Leon-Casasola OA. Multimodal approaches to the management of neuropathic pain: The role of topical analgesia. J Pain Symptom Manag. 2007;33(3):356-364.
4. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005;252(6):677-686.
5. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: Double blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39-44.
6. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrolment study. Pain. 1999;80: 533-538.
7. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393-408.
8. Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post herpetic neuralgia: Results of a long-term study. Curr Med Res Opin. 2009;25(5):1295-1305.
9. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Arch Neurol. 2003;60(11):1524-1534.
10. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005;118(3):289-305.
11. Acevedo JC, Amaya A, de León Casasola O, et al. [Guidelines for the diagnosis and management of neuropathic pain: consensus of a group of Latin American experts]. Rev Iberoamericana del Dolor. 2008;2: 15-46.
12. Haanpää M. Mechanism-based treatment of herpes zoster and postherpetic neuralgia. Eur J Pain. 2007;11(1):38.
13. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7): 1607-1619.
14. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagn ostic questionnaire (DN4). Pain. 2005;114(1-2):29-36.
15. Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66.
16. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978;3(3):177-201.
17. Estes NA, Manolis AS, Greenblatt DJ, Garan H, Ruskin JN. Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. Am Heart J. 1989;117(5):1060-1064.
18. Jürgens G, Graudal NA, Kampmann JP. Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet. 2003;42:647-663.
19. Gianelly R, von der Groeben JO, Spivack AP, Harrison DC. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med. 1967;277(23):1215-1219.
20. Lie KI, Wellens HJJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation: A double-blind, randomized study of 212 consecutive patients. N Engl J Med. 1974;291(25): 1324-1326.
21. Hans G, Joukes E, Verhulst J, Vercauteren M. Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: Study of 40 consecutive cases. Curr Med Res Opin. 2009; 25(11):2737-2743.
22. Davies PS, Galer BS. Review of 5% lidocaine medicated plaster studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9): 937-947.
23. Barbano RL, Hermann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914-918.
24. Nayak S, Cunliffe M. Case report: Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: Report of five cases. Pediatric Anesthesia. 2008;18(6):554-558.
25. Liedgens H, Hertel N, Gabriel A, et al. Cost-effectiveness analysis of a 5% lidocaine medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: A German perspective. Clin Drug Investig. 2008;28(9):583-601.
26. Ritchie M, Liedgens H, Nuijten M. Cost effectiveness of a 5% lidocaine medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: A Markov model analysis. Clin Drug Investig. 2010;30(2):71-87.
27. Gustorff B. Topical lidocaine - experimental models of neuropathic pain and implications for symptomatic treatment. Eur J Pain. 2007; 11(S1):S55.
28. Sjölund KF, Segerdahl M, Sollevi A. Adenosine reduces secondary hyperalgesia in two human models of cutaneous inflammatory pain. Anesth Analg. 1999;88(3):605-610.
29. Ando K, Wallace MS, Braun J, Schulteis G. Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: A double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med. 2000;25(5): 468-474.
30. Sycha T, Anzenhofer S, Lehr S, et al. Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: A randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain. 2005;113(3):316-322.